These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 22534406)

  • 1. Added predictive ability of the CHA2DS2VASc risk score for stroke and death in patients with atrial fibrillation: the prospective Danish Diet, Cancer, and Health cohort study.
    Larsen TB; Lip GY; Skjøth F; Due KM; Overvad K; Hvilsted Rasmussen L
    Circ Cardiovasc Qual Outcomes; 2012 May; 5(3):335-42. PubMed ID: 22534406
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reliable identification of "truly low" thromboembolic risk in patients initially diagnosed with "lone" atrial fibrillation: the Belgrade atrial fibrillation study.
    Potpara TS; Polovina MM; Licina MM; Marinkovic JM; Prostran MS; Lip GY
    Circ Arrhythm Electrophysiol; 2012 Apr; 5(2):319-26. PubMed ID: 22319004
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognosis in patients with atrial fibrillation and CHA2DS2-VASc Score = 0 in a community-based cohort study.
    Taillandier S; Olesen JB; Clémenty N; Lagrenade I; Babuty D; Lip GY; Fauchier L
    J Cardiovasc Electrophysiol; 2012 Jul; 23(7):708-13. PubMed ID: 22268375
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0-1: a nationwide cohort study.
    Olesen JB; Torp-Pedersen C; Hansen ML; Lip GY
    Thromb Haemost; 2012 Jun; 107(6):1172-9. PubMed ID: 22473219
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk stratification schemes, anticoagulation use and outcomes: the risk--treatment paradox in patients with newly diagnosed non-valvular atrial fibrillation.
    Sandhu RK; Bakal JA; Ezekowitz JA; McAlister FA
    Heart; 2011 Dec; 97(24):2046-50. PubMed ID: 22076011
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive value of the CHA2DS2-VASc score in atrial fibrillation patients at high risk for stroke despite oral anticoagulation.
    Jover E; Roldán V; Gallego P; Hernández-Romero D; Valdés M; Vicente V; Lip GY; Marín F
    Rev Esp Cardiol (Engl Ed); 2012 Jul; 65(7):627-33. PubMed ID: 22609214
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The CHA2DS2-VASc score identifies those patients with atrial fibrillation and a CHADS2 score of 1 who are unlikely to benefit from oral anticoagulant therapy.
    Coppens M; Eikelboom JW; Hart RG; Yusuf S; Lip GY; Dorian P; Shestakovska O; Connolly SJ
    Eur Heart J; 2013 Jan; 34(3):170-6. PubMed ID: 23018151
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modification of outcomes with aspirin or apixaban in relation to CHADS(2) and CHA(2)DS(2)-VASc scores in patients with atrial fibrillation: a secondary analysis of the AVERROES study.
    Lip GY; Connolly S; Yusuf S; Shestakovska O; Flaker G; Hart R; Lanas F; Xavier D; Eikelboom J;
    Circ Arrhythm Electrophysiol; 2013 Feb; 6(1):31-8. PubMed ID: 23390125
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study.
    Friberg L; Rosenqvist M; Lip GY
    Eur Heart J; 2012 Jun; 33(12):1500-10. PubMed ID: 22246443
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stroke risk stratification in a "real-world" elderly anticoagulated atrial fibrillation population.
    Poli D; Lip GY; Antonucci E; Grifoni E; Lane D
    J Cardiovasc Electrophysiol; 2011 Jan; 22(1):25-30. PubMed ID: 20653814
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Net clinical benefit of warfarin in patients with atrial fibrillation: a report from the Swedish atrial fibrillation cohort study.
    Friberg L; Rosenqvist M; Lip GY
    Circulation; 2012 May; 125(19):2298-307. PubMed ID: 22514252
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohorts.
    Piccini JP; Stevens SR; Chang Y; Singer DE; Lokhnygina Y; Go AS; Patel MR; Mahaffey KW; Halperin JL; Breithardt G; Hankey GJ; Hacke W; Becker RC; Nessel CC; Fox KA; Califf RM;
    Circulation; 2013 Jan; 127(2):224-32. PubMed ID: 23212720
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CHADS(2) and CHA(2)DS(2)-VASc scores in the prediction of clinical outcomes in patients with atrial fibrillation after catheter ablation.
    Chao TF; Lin YJ; Tsao HM; Tsai CF; Lin WS; Chang SL; Lo LW; Hu YF; Tuan TC; Suenari K; Li CH; Hartono B; Chang HY; Ambrose K; Wu TJ; Chen SA
    J Am Coll Cardiol; 2011 Nov; 58(23):2380-5. PubMed ID: 22115643
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Net clinical benefit of antithrombotic therapy in patients with atrial fibrillation and chronic kidney disease: a nationwide observational cohort study.
    Bonde AN; Lip GY; Kamper AL; Hansen PR; Lamberts M; Hommel K; Hansen ML; Gislason GH; Torp-Pedersen C; Olesen JB
    J Am Coll Cardiol; 2014 Dec; 64(23):2471-82. PubMed ID: 25500231
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison between CHADS2 and CHA2 DS2 -VASc score in a stroke cohort with atrial fibrillation.
    Giralt-Steinhauer E; Cuadrado-Godia E; Ois A; Jiménez-Conde J; Rodríguez-Campello Á; Soriano C; Roquer J
    Eur J Neurol; 2013 Apr; 20(4):623-8. PubMed ID: 22834861
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Should we recommend oral anticoagulation therapy in patients with atrial fibrillation undergoing coronary artery stenting with a high HAS-BLED bleeding risk score?
    Ruiz-Nodar JM; Marín F; Roldán V; Valencia J; Manzano-Fernández S; Caballero L; Hurtado JA; Sogorb F; Valdés M; Lip GY
    Circ Cardiovasc Interv; 2012 Aug; 5(4):459-66. PubMed ID: 22787018
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vascular disease and stroke risk in atrial fibrillation: a nationwide cohort study.
    Olesen JB; Lip GY; Lane DA; Køber L; Hansen ML; Karasoy D; Hansen CM; Gislason GH; Torp-Pedersen C
    Am J Med; 2012 Aug; 125(8):826.e13-23. PubMed ID: 22579139
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral anticoagulation, aspirin, or no therapy in patients with nonvalvular AF with 0 or 1 stroke risk factor based on the CHA2DS2-VASc score.
    Lip GY; Skjøth F; Rasmussen LH; Larsen TB
    J Am Coll Cardiol; 2015 Apr; 65(14):1385-94. PubMed ID: 25770314
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Implications of the CHA(2)DS(2)-VASc and HAS-BLED Scores for thromboprophylaxis in atrial fibrillation.
    Lip GY
    Am J Med; 2011 Feb; 124(2):111-4. PubMed ID: 20887966
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CHADS2 and CHA2DS2-VASc risk factors to predict first cardiovascular hospitalization among atrial fibrillation/atrial flutter patients.
    Naccarelli GV; Panaccio MP; Cummins G; Tu N
    Am J Cardiol; 2012 May; 109(10):1526-33. PubMed ID: 22360819
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.